We don't know whether the most recent response to this request contains information or not – if you are M Williams please sign in and let everyone know.

Oestradiol (Estradot) patches, Oestradiol gel and other products

M Williams made this Official Information request to Pharmaceutical Management Agency

This request has an unknown status. We're waiting for M Williams to read recent responses and update the status.

From: M Williams

Dear Pharmaceutical Management Agency,

Please provide the following information:
- All correspondence relating to the Pharmac's management of the supply issue for Oestradiol (Estradot) patches, Oestradiol gel and other products. Including correspondence to Pharmacists, wholesalers, distributors, hospital pharmacists, Ministry of Health, Public Health Agency, Consumers and Advocacy Groups, PHO's and primary care organisations and other interested parties (From 2022 onwards)

- Correspondence and documents that relate to Pharmac's most recent decision to Request for Proposals for supply of transdermal oestriadol products. Please include documentation regarding the announced Tender process and current status (From 2022 onwards).

- Internal Policies and/or guidance relating to the management and access to Oestradiol (Estradot) patches, Oestradiol gel and other products.

- Correspondence and documentation that evidence Pharmac have considered the following in their management of the supply issue for Oestradiol (Estradot) patches, Oestradiol gel and other products - Impact on the wellbeing of people who are unable to receive the treatment they need, alignment with Pharmac's Achieving access equity, Human Rights considerations i.e. discrimination on the grounds of Gender and Disability, number of complaints received about the supply issue/Pharmac's management of the issue

- budget assigned to resolving the supply issue of Oestradiol (Estradot) patches, Oestradiol gel and other products.

Yours faithfully,

M Williams

Link to this

From: Web Enquiry
Pharmaceutical Management Agency

Kia ora,

Thank you for your request for information, under the Official Information Act 1982.

You will receive a response no later than 20 working days after receipt of your request.

Thank you
Government Services - Pharmac

-----Original Message-----
From: M Williams <[FOI #26968 email]>
Sent: Friday, May 24, 2024 7:10 AM
To: Web Enquiry <[email address]>
Subject: Official Information request - Oestradiol (Estradot) patches, Oestradiol gel and other products

[You don't often get email from [FOI #26968 email]. Learn why this is important at https://aka.ms/LearnAboutSenderIdentific... ]

Dear Pharmaceutical Management Agency,

Please provide the following information:
- All correspondence relating to the Pharmac's management of the supply issue for Oestradiol (Estradot) patches, Oestradiol gel and other products. Including correspondence to Pharmacists, wholesalers, distributors, hospital pharmacists, Ministry of Health, Public Health Agency, Consumers and Advocacy Groups, PHO's and primary care organisations and other interested parties (From 2022 onwards)

- Correspondence and documents that relate to Pharmac's most recent decision to Request for Proposals for supply of transdermal oestriadol products. Please include documentation regarding the announced Tender process and current status (From 2022 onwards).

- Internal Policies and/or guidance relating to the management and access to Oestradiol (Estradot) patches, Oestradiol gel and other products.

- Correspondence and documentation that evidence Pharmac have considered the following in their management of the supply issue for Oestradiol (Estradot) patches, Oestradiol gel and other products - Impact on the wellbeing of people who are unable to receive the treatment they need, alignment with Pharmac's Achieving access equity, Human Rights considerations i.e. discrimination on the grounds of Gender and Disability, number of complaints received about the supply issue/Pharmac's management of the issue

- budget assigned to resolving the supply issue of Oestradiol (Estradot) patches, Oestradiol gel and other products.

Yours faithfully,

M Williams

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #26968 email]

Is [PHARMAC request email] the wrong address for Official Information requests to Pharmaceutical Management Agency? If so, please contact us using this form:
https://fyi.org.nz/change_request/new?bo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://fyi.org.nz/help/officers

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.

hide quoted sections

Link to this

From: Web Enquiry
Pharmaceutical Management Agency


Attachment OIA response M Williams.pdf
160K Download View as HTML


Kia ora,

Please find a response to your Official Information Act request attached.

Thank you
Government Services - Pharmac

-----Original Message-----
From: M Williams <[FOI #26968 email]>
Sent: Friday, May 24, 2024 7:10 AM
To: Web Enquiry <[email address]>
Subject: Official Information request - Oestradiol (Estradot) patches, Oestradiol gel and other products

[You don't often get email from [FOI #26968 email]. Learn why this is important at https://aka.ms/LearnAboutSenderIdentific... ]

Dear Pharmaceutical Management Agency,

Please provide the following information:
- All correspondence relating to the Pharmac's management of the supply issue for Oestradiol (Estradot) patches, Oestradiol gel and other products. Including correspondence to Pharmacists, wholesalers, distributors, hospital pharmacists, Ministry of Health, Public Health Agency, Consumers and Advocacy Groups, PHO's and primary care organisations and other interested parties (From 2022 onwards)

- Correspondence and documents that relate to Pharmac's most recent decision to Request for Proposals for supply of transdermal oestriadol products. Please include documentation regarding the announced Tender process and current status (From 2022 onwards).

- Internal Policies and/or guidance relating to the management and access to Oestradiol (Estradot) patches, Oestradiol gel and other products.

- Correspondence and documentation that evidence Pharmac have considered the following in their management of the supply issue for Oestradiol (Estradot) patches, Oestradiol gel and other products - Impact on the wellbeing of people who are unable to receive the treatment they need, alignment with Pharmac's Achieving access equity, Human Rights considerations i.e. discrimination on the grounds of Gender and Disability, number of complaints received about the supply issue/Pharmac's management of the issue

- budget assigned to resolving the supply issue of Oestradiol (Estradot) patches, Oestradiol gel and other products.

Yours faithfully,

M Williams

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #26968 email]

Is [PHARMAC request email] the wrong address for Official Information requests to Pharmaceutical Management Agency? If so, please contact us using this form:
https://fyi.org.nz/change_request/new?bo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://fyi.org.nz/help/officers

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.

hide quoted sections

Link to this

We don't know whether the most recent response to this request contains information or not – if you are M Williams please sign in and let everyone know.

Things to do with this request

Anyone:
Pharmaceutical Management Agency only: